Company Data
BioLineRx Ltd.
Ticker
BLRX
Current Price
$5.25 38.49%
Market Cap
$19.5M
Price Target
Refer to Report
Volume
36.4M
52wk Range
$2.3001 - $35.6
Overview
BioLine Rx Ltd is a clinical-stage biopharmaceutical development company with a strategic focus on oncology. Its development and commercialization pipeline consists of two clinical-stage therapeutic candidates – Motixafortide, a novel peptide for the treatment of solid tumors, hematological malignancies and stem cell mobilization, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, it has an off- strategy, a legacy therapeutic product called BL-5010 for the treatment of skin lesions.